CoChat

Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Full, persistent blockade of central neurokinin-1 (NK1) receptors may be a potential antidepressant mechanism. The selective NK1 antagonist orvepitant (GW823296) was used to test this hypothesis. A preliminary positron emission tomography study in eight male volunteers drove dose selection for two randomized six week studies in patients with major depressive disorder (MDD). Displacement of central [ 11 C]GR205171 binding indicated that oral orvepitant doses of 30–60 mg/day provided >99% receptor occupancy for ≥24 h. Studies 733 and 833 randomized patients with MDD and 17-item Hamilton Depression Rating Scale (HAM-D)≥22 to double-blind treatment with orvepitant 30 mg/day, orvepitant 60 mg/day or placebo (1:1:1). Primary outcome measure was change from baseline in 17-item HAM-D total score at Week 6 analyzed using mixed models repeated measures. Study 733 ( n=328) demonstrated efficacy on the primary endpoint (estimated drug-placebo differences of 30 mg: −2.41, 95% confidence interval (CI) (−4.50 to −0.31) p=0.0245; 60 mg: –2.86, 95% CI (−4.97 to −0.75) p=0.0082). Study 833 ( n=345) did not show significance (estimated drug-placebo differences of 30 mg: −1.67, 95% CI (−3.73 to 0.39) p=0.1122; 60 mg: −0.76, 95% CI (−2.85 to 1.32) p=0.4713). The results support the hypothesis that full, long lasting blockade of central NK1 receptors may be an efficacious mechanism for the treatment of MDD.

Overview

Integrity signals

Registry

Crossref · 10.1177/0269881113480990

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 38 references

Research works printed but not linked: 8

  1. Carletti R, 2005, Eur Neuropsychopharmacol, 15, S539
  2. Chappell P, 2002, Curr Pharm Des, 11, 1529
  3. Fava M, 2006, J Clin Psychiatry, 67, S14
  4. First MB, 2002, Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition
  5. Hargreaves R, 2002, J Clin Psychiatry, 63, S18
  6. Luthra SK, 1993, J Labelled Comp Radiopharm, 32, 518
  7. 10.1073/pnas.98.4.1912 · doi:10.1073/pnas.98.4.1912 · Paper page
  8. 10.1111/j.1755-5949.2008.00038.x · doi:10.1111/j.1755-5949.2008.00038.x

Cited by

See all 71

Metadata

Authors
Ratti, E., Bettica, P., Alexander, R., Archer, G., Carpenter, D., Evoniuk, G., Gomeni, R., Lawson, E., Lopez, M., Millns, H., Rabiner, E. A., Trist, D., Trower, M., Zamuner, S., Krishnan, R., & Fava, M.
Affiliations
  • GlaxoSmithKline (Italy) (IT)
  • GlaxoSmithKline (United Kingdom) (GB)
  • GlaxoSmithKline Research and Development, Research Triangle Park, NC, USA
  • Pharmacometrics, GlaxoSmithKline, Upper Merion, USA
  • National University of Singapore (SG)
  • Department of Psychiatry, Massachusetts General Hospital, Boston, USA
Venue
Journal of Psychopharmacology
Published
2013-03-28
Volume
27
Issue
5
Pages
424-434
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W2073690654
Cited by
69
References
38
Citations by year
2026: 3 · 2025: 2 · 2024: 11 · 2023: 9 · 2022: 1 · 2021: 5 · 2020: 5 · 2019: 7 · 2018: 2 · 2017: 8 · 2016: 3 · 2015: 4 · 2014: 4 · 2013: 5
FWCI
4.16
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • National University of Singapore (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
neurokinin-1 receptor, major depressive disorder, antidepressant mechanism, receptor occupancy, dose selection, Hamilton Depression Rating Scale
MeSH terms
Adult, Aged, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Humans, Male, Middle Aged, Piperidines, Radioligand Assay, Bridged Bicyclo Compounds, Heterocyclic, Positron-Emission Tomography, Neurokinin-1 Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. https://app.cochat.ai/papers/10.1177/0269881113480990
The paper
Ratti, E., Bettica, P., Alexander, R., Archer, G., Carpenter, D., Evoniuk, G., Gomeni, R., Lawson, E., Lopez, M., Millns, H., Rabiner, E. A., Trist, D., Trower, M., Zamuner, S., Krishnan, R., & Fava, M. (2013). Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. Journal of Psychopharmacology. https://doi.org/10.1177/0269881113480990

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.